Metabolic Stability for Drug Discovery and Development
暂无分享,去创建一个
[1] R. Wattiaux,et al. Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. , 1955, The Biochemical journal.
[2] Grant R. Wilkinson,et al. A physiological approach to hepatic drug clearance , 1975 .
[3] M. Rowland,et al. Hepatic elimination--dispersion model. , 1985, Journal of pharmaceutical sciences.
[4] C. Hansch,et al. Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.
[5] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[6] Jeffrey P. Jones,et al. Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[7] C. Waller,et al. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[8] K. Korzekwa,et al. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. , 1996, Methods in enzymology.
[9] Barry C. Jones,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 1: active site characteristics , 1997 .
[10] J B Houston,et al. Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. , 1997, Drug metabolism reviews.
[11] Dennis A. Smith,et al. Properties of cytochrome P450 isoenzymes and their substrates Part 2: properties of cytochrome P450 substrates , 1997 .
[12] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[13] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[14] J. Strong,et al. Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. , 1997, The Journal of pharmacology and experimental therapeutics.
[15] J B Houston,et al. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. , 1997, Drug metabolism and disposition: the biological fate of chemicals.
[16] P. Ortiz de Montellano,et al. Structure-function of cytochromes P450 and flavin-containing monooxygenases: implications for drug metabolism. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[17] Y. Sugiyama,et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. , 1998, Annual review of pharmacology and toxicology.
[18] F. Oesch,et al. Drug metabolizing capacity of cryopreserved human, rat, and mouse liver parenchymal cells in suspension. , 1999, Drug Metabolism And Disposition.
[19] J. Venhorst,et al. Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. , 1999, Chemical research in toxicology.
[20] N. Bodor,et al. Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of noncongener carboxylic esters. , 1999, Journal of medicinal chemistry.
[21] G. L. Kedderis,et al. Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. , 1999, Chemico-biological interactions.
[22] D. Lewis,et al. Cytochrome P450 Substrate Specificities, Substrate Structural Templates and Enzyme Active Site Geometries , 1999, Drug metabolism and drug interactions.
[23] A. Alex,et al. A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.
[24] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[25] J. Houston,et al. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.
[26] D. Lewis,et al. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human p450 substrate specificity and metabolism. , 2000, Biochemical pharmacology.
[27] J. Miners,et al. Nonspecific binding of drugs to human liver microsomes. , 2000, British journal of clinical pharmacology.
[28] D. Greenblatt,et al. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. , 2000, The Journal of pharmacology and experimental therapeutics.
[29] David W. Opitz,et al. Use of Statistical and Neural Net Approaches in Predicting Toxicity of Chemicals , 2000, J. Chem. Inf. Comput. Sci..
[30] I. A. D. de Graaf,et al. Increased post-thaw viability and phase I and II biotransformation activity in cryopreserved rat liver slices after improvement of a fast-freezing method. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[31] John G. Topliss,et al. QSAR Model for Drug Human Oral Bioavailability1 , 2000 .
[32] S. Ekins,et al. Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance. , 2000, The Journal of pharmacology and experimental therapeutics.
[33] R. E. White,et al. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. , 2000, Annual review of pharmacology and toxicology.
[34] A. Sohlenius-Sternbeck,et al. High conservation of both phase I and II drug-metabolizing activities in cryopreserved rat liver slices , 2000, Xenobiotica; the fate of foreign compounds in biological systems.
[35] D. Lewis. Modelling Human Cytochromes P450 for Evaluating Drug Metabolism: An Update , 2000, Drug metabolism and drug interactions.
[36] D E McRee,et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. , 2000, Molecular cell.
[37] J. Barrett. MOLECULAR AND ENVIRONMENTAL CAUSES OF CANCER , 2000, Drug metabolism reviews.
[38] D. Cross,et al. A COMMENTARY ON THE USE OF HEPATOCYTES IN DRUG METABOLISM STUDIES DURING DRUG DISCOVERY AND DEVELOPMENT* , 2000, Drug metabolism reviews.
[39] Y. Ishii,et al. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[40] P. Jeffrey,et al. Utility of metabolic stability screening: comparison of in vitro and in vivo clearance , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[41] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[42] S. Surapaneni,et al. Role of drug metabolism in drug discovery and development , 2001, Medicinal research reviews.
[43] C. Masimirembwa,et al. In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. , 2001, Combinatorial chemistry & high throughput screening.
[44] W. L. Nelson,et al. Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol analogs: metabolism by CYP1A2. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[45] C. Masimirembwa,et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. , 2001, Molecular pharmacology.
[46] D. Greenblatt,et al. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. , 2001, The Journal of pharmacology and experimental therapeutics.
[47] T N Thompson,et al. Optimization of metabolic stability as a goal of modern drug design , 2001, Medicinal research reviews.
[48] Gerd Folkers,et al. Pharmacokinetic optimization in drug research , 2001 .
[49] Sean Ekins,et al. Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.
[50] Anthony Long,et al. Computer systems for the prediction of xenobiotic metabolism. , 2002, Advanced drug delivery reviews.
[51] N. Takenaga,et al. Structure-activity relationship in O-glucuronidation of indolocarbazole analogs. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[52] Sean Ekins,et al. A pharmacophore for human pregnane X receptor ligands. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[53] Gabriele Cruciani,et al. Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. , 2003, Journal of medicinal chemistry.
[54] M. Morris,et al. Membrane Transport in Hepatic Clearance of Drugs I: Extended Hepatic Clearance Models Incorporating Concentration-Dependent Transport and Elimination Processes , 1997, Pharmaceutical Research.
[55] R. J. Riley,et al. Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.
[56] Michael S. Roberts,et al. A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations , 1986, Journal of Pharmacokinetics and Biopharmaceutics.
[57] Malcolm Rowland,et al. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[58] Malcolm Rowland,et al. Clearance concepts in pharmacokinetics , 1973, Journal of Pharmacokinetics and Biopharmaceutics.